metabolic research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== Further reading == Wolf, Jeanne; Ali Larter, Always the Bad Girl; Parade; August 24, 2009; Retrieved July 24, 2010 Cavaco, Paul; Ali Larter: Her Allure Photo Shoot; Allure; Retrieved July 24, 2010 Our Heroine; Cosmopolitan; Retrieved July 24, 2010 Hiltbrand, David; Split personalities make solid role for Ali Larter; Chicago Tribune; January 31, 2007; Retrieved July 24, 2010 Longsdorf, Amy; 'Obsessed' star Ali Larter calls Allentown area a 'safe haven'; The Morning Call; April 26, 2009; Retrieved July 26, 2010 Passafuime, Rocco; Still Our Hottest Hero; The Cinema Source; September 18, 2010; Retrieved September 25, 2010
=== Sony Computer Entertainment === In 1997, Ueda joined Sony Computer Entertainment Japan. He began work on Ico, being granted his own unit as the studio had little experience in developing games on their own (mostly the Ape Escape series) due to their focus on assisting third-party developers. After Ico, Ueda and his small team started work on Shadow of the Colossus. In February 2007, Japanese gaming magazine Famitsu reported that Ueda and his team were working on a game for the PlayStation 3. No details about the unnamed title were revealed. In 2008, in the August edition of PlayStation Magazine, Sony Worldwide Studios boss Shuhei Yoshida commented that both Ico and Shadow of the Colossus took 4 years to develop as a hint that the game was under production, but was not close to release. The game was revealed at E3 2009 as The Last Guardian, the trailer for which suggests a saga involving elements of both Ico and Shadow of the Colossus wherein a young boy resembling Ico partners up with a colossus-sized companion to complete puzzles. Ueda later confirmed The Last Guardian to be related to the two previous installments. In an interview with G4tv.com in 2009 he expressed admiration for the method of cut-scene story-telling in Valve's Half-Life 2, and when questioned directly expressed an interest in making a first-person game.
=== Preliminary health research === Preliminary research remains sparse and inconclusive. In a 2015 systematic review, most of the studies did not show an effect of chia seed consumption on cardiovascular risk factors in humans.
=== Miscellaneous === Mogo appears in the Injustice: Gods Among Us prequel comic. He travels to Earth with the Green Lantern Corps to combat Superman's Regime and the Sinestro Corps until Superman pushes him into Earth's sun.
Sources: en.wikipedia.org
=== 22 SAS Regiment === Since serving in Malaya, men from the regular army 22 SAS Regiment have taken part in reconnaissance patrols and large scale raiding missions in the Jebel Akhdar War in Oman and conducted covert reconnaissance and surveillance patrols and some larger scale raiding missions in Borneo during the Indonesia–Malaysia confrontation. They returned to Oman in operations against Communist-backed rebels in the Dhofar Rebellion including the Battle of Mirbat. They have also taken part in operations in the Aden Emergency, Northern Ireland, and Gambia. Their Special projects team assisted the West German counterterrorism group GSG 9 at Mogadishu, with Lufthansa Flight 181. The SAS counter terrorist wing famously took part in a hostage rescue operation during the Iranian Embassy Siege in London. SAS were involved throughout Britain's covert involvement in the Soviet–Afghan War; they acted through private military contractor Keenie Meenie Services (or KMS Ltd), training the Afghan Mujaheddin in weapons, tactics and using explosives. They trained the Mujaheddin in Afghanistan and sent them to be trained in Pakistan, Oman and parts of the UK. During the Falklands War B squadron were prepared for Operation Mikado before it was subsequently cancelled while D and G squadrons were deployed and participated in the raid on Pebble Island. Operation Flavius was a controversial operation in Gibraltar against the Provisional Irish Republican Army (PIRA). 22 SAS directed NATO aircraft onto Serb positions and hunted war criminals in Bosnia.
In the Western hemisphere, tostones (also known as banann peze in Haiti, tachinos or chatinos in Cuba, and patacones in Colombia, Costa Rica, Ecuador, Honduras, Panama, Peru and Venezuela) are twice-fried plantain fritters, often served as a side dish, appetizer or snack. Plantains are sliced in 4 cm (2 in) long pieces and fried in oil. The segments are then removed and individually smashed down to about half their original height. Finally, the pieces are fried again and then seasoned, often with salt. In some countries, such as Cuba, Puerto Rico and the Dominican Republic, the tostones are dipped in Creole sauce from chicken, pork, beef, or shrimp before eating. In Haiti, bannann peze is commonly served with pikliz, a slaw-like condiment made with cabbage, onions, carrots and scotch bonnet peppers. In Nicaragua, tostones are typically served with fried cheese (Tostones con queso) and sometimes with refried beans. While the name tostones is used to describe this food when prepared at home, in some South American countries the word also describes plantain chips, which are typically purchased from a store. In western Venezuela, much of Colombia and the Peruvian Amazon, patacones are a frequently seen variation of tostones. Plantains are sliced in long pieces and fried in oil, then used to make sandwiches with pork, beef, chicken, vegetables and ketchup. They can be made with unripe patacon verde or ripe patacon amarillo plantains.
== History == Frank P. Cotter developed a "simple self sealing check valve, adapted to be connected in the pipe connections without requiring special fittings and which may be readily opened for inspection or repair" 1907 (U.S. patent 865,631). Nikola Tesla invented a deceptively simple one-way valve for fluids in 1916, called a Tesla valve. It was patented in 1920 (U.S. patent 1,329,559).
=== Tetrazine ligation === The tetrazine ligation is the reaction of a trans-cyclooctene and an s-tetrazine in an inverse-demand Diels Alder reaction followed by a retro-Diels Alder reaction to eliminate nitrogen gas. The reaction is extremely rapid with a second order rate constant of 2000 M−1–s−1 (in 9:1 methanol/water) allowing modifications of biomolecules at extremely low concentrations.
== Naval career == Upon his graduation from Tufts, Bello was commissioned an ensign in the United States Navy and served a four-year tour that included a tour of duty in South Vietnam as supply officer for PBR Mobile Base II on the Mekong Delta with a mission of combat support for several Patrol Boat, River (PBR) squadrons. He was awarded the Navy Commendation Medal with Combat V for meritorious service. In 1972, after Vietnam, Bello was assigned to the Moffett Field Naval Air Station Moffett Field as the Navy Exchange Officer. He resigned his commission as a Lieutenant to attend graduate school.
Sources: en.wikipedia.org
=== T-cell hypothesis === Populations of regulatory T cells are believed to be responsible for the onset of the disease. When there is a decline of these cells, manifestations of diseases begin to appear, giving an idea of the vital role of these cells in the prevention of autoimmune diseases. Moreover, an additional decrease could, unfortunately, worsen the pathological state and lead to the differentiation of an undifferentiated connective tissue disease into a differentiated connective tissue disease with a poorer prognosis. Due to the wide range of variation in the inclusion criteria of the disease, up to 50% of patients diagnosed with connective tissue disease may have undifferentiated disease of the underlying connective tissue.
No statistically significant correlation between penis size and the size of other body parts has been found in research. Some environmental factors in addition to genetics, such as the presence of endocrine disruptors, can affect penis growth.
Most members of the 102d Regiment of Foot embarked for England in May 1810. Upon arrival, a majority went to veteran or garrison battalions, most officers ending up in the 8th Royal Veteran Battalion. The regiment was reconstituted with new recruits, including 150 men "of free birth and good character" born in the colony of New South Wales, after it arrived at its new base in Horsham in October 1810. It was sent to Guernsey in July 1811. The regiment was posted to the Bermuda Garrison, stationed at St. George's Garrison in 1812, this being part of the Nova Scotia Command, co-inciding with the start of the War of 1812.
=== Parallel MRI === It takes time to gather MRI data using sequential applications of magnetic field gradients. Even for the most streamlined of MRI sequences, there are physical and physiologic limits to the rate of gradient switching. Parallel MRI circumvents these limits by gathering some portion of the data simultaneously, rather than in a traditional sequential fashion. This is accomplished using arrays of radiofrequency (RF) detector coils, each with a different 'view' of the body. A reduced set of gradient steps is applied, and the remaining spatial information is filled in by combining signals from various coils, based on their known spatial sensitivity patterns. The resulting acceleration is limited by the number of coils and by the signal to noise ratio (which decreases with increasing acceleration), but two- to four-fold accelerations may commonly be achieved with suitable coil array configurations, and substantially higher accelerations have been demonstrated with specialized coil arrays. Parallel MRI may be used with most MRI sequences. After a number of early suggestions for using arrays of detectors to accelerate imaging went largely unremarked in the MRI field, parallel imaging saw widespread development and application following the introduction of the simultaneous acquisition of spatial harmonics (SMASH) technique in 1996–7. The sensitivity encoding (SENSE) and generalized autocalibrating partially parallel acquisitions (GRAPPA) techniques are the parallel imaging methods in most common use today.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.